{"name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","slug":"suzhou-suncadia-biopharmaceuticals-co-ltd","ticker":"","exchange":"","domain":"suzhousuncadiabiopharmaceuticals.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":18,"colorKey":"oncology","drugs":[{"name":"SHR-1701、CAPOX","genericName":"SHR-1701、CAPOX","slug":"shr-1701-capox","indication":"Gastric cancer or gastroesophageal junction cancer (in combination with CAPOX)","status":"phase_3"},{"name":"Hydroxycamptothecin for Injection","genericName":"Hydroxycamptothecin for Injection","slug":"hydroxycamptothecin-for-injection","indication":"Colorectal cancer","status":"phase_3"},{"name":"Mitomycin for Injection","genericName":"Mitomycin for Injection","slug":"mitomycin-for-injection","indication":"Gastric cancer","status":"phase_3"},{"name":"SHR-A2102 and Adebrelimab","genericName":"SHR-A2102 and Adebrelimab","slug":"shr-a2102-and-adebrelimab","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"TAS-102, Regorafenib , Fruquintinib","genericName":"TAS-102, Regorafenib , Fruquintinib","slug":"tas-102-regorafenib-fruquintinib","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"platinum-based dual-agent chemotherapy","genericName":"platinum-based dual-agent chemotherapy","slug":"platinum-based-dual-agent-chemotherapy","indication":"Advanced or metastatic solid tumors (specific indication pending phase 3 trial results)","status":"phase_3"},{"name":"Adebrelimab combined with chemotherapy","genericName":"Adebrelimab combined with chemotherapy","slug":"adebrelimab-combined-with-chemotherapy","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"BCG for Injection","genericName":"BCG for Injection","slug":"bcg-for-injection","indication":"Non-muscle-invasive bladder cancer (NMIBC), high-grade or recurrent","status":"phase_3"},{"name":"Calcium Folinate Injection","genericName":"Calcium Folinate Injection","slug":"calcium-folinate-injection","indication":"Methotrexate toxicity rescue in high-dose methotrexate chemotherapy","status":"phase_3"},{"name":"Epirubicin Hydrochloride for Injection","genericName":"Epirubicin Hydrochloride for Injection","slug":"epirubicin-hydrochloride-for-injection","indication":"Breast cancer (adjuvant and metastatic)","status":"phase_3"},{"name":"Fluorouracil Injection","genericName":"Fluorouracil Injection","slug":"fluorouracil-injection","indication":"Colorectal cancer","status":"marketed"},{"name":"Gemcitabine and cisplatin / carboplatin","genericName":"Gemcitabine and cisplatin / carboplatin","slug":"gemcitabine-and-cisplatin-carboplatin","indication":"Advanced or metastatic non-small cell lung cancer","status":"phase_3"},{"name":"Pirarubicin Hydrochloride for Injection","genericName":"Pirarubicin Hydrochloride for Injection","slug":"pirarubicin-hydrochloride-for-injection","indication":"Advanced breast cancer","status":"phase_3"},{"name":"Placebo、CAPOX","genericName":"Placebo、CAPOX","slug":"placebo-capox","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"SHR-1501 for Injection","genericName":"SHR-1501 for Injection","slug":"shr-1501-for-injection","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"SHR-A1811 for Injection","genericName":"SHR-A1811 for Injection","slug":"shr-a1811-for-injection","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"SHR-A2009 ; Aumolertinib","genericName":"SHR-A2009 ; Aumolertinib","slug":"shr-a2009-aumolertinib","indication":"Non-small cell lung cancer with EGFR T790M mutation after progression on prior EGFR-TKI therapy","status":"phase_3"},{"name":"SHR-A2009 monotherapy","genericName":"SHR-A2009 monotherapy","slug":"shr-a2009-monotherapy","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"tislelizumab, and platinum-based chemotherapy","genericName":"tislelizumab, and platinum-based chemotherapy","slug":"tislelizumab-and-platinum-based-chemotherapy","indication":"Other","status":"phase_3"},{"name":"Adebrelimab；platinum-based chemotherapy","genericName":"Adebrelimab；platinum-based chemotherapy","slug":"adebrelimab-platinum-based-chemotherapy","indication":"Other","status":"phase_1"},{"name":"Ametinib mesylate","genericName":"Ametinib mesylate","slug":"ametinib-mesylate","indication":"Other","status":"phase_1"},{"name":"BP-102","genericName":"BP-102","slug":"bp-102","indication":"Other","status":"phase_1"},{"name":"SHR-2017 injection","genericName":"SHR-2017 injection","slug":"shr-2017-injection","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"SHR-1701、CAPOX","genericName":"SHR-1701、CAPOX","slug":"shr-1701-capox","phase":"phase_3","mechanism":"SHR-1701 is a PD-L1 inhibitor combined with CAPOX chemotherapy (capecitabine and oxaliplatin) to enhance anti-tumor immunity while delivering cytotoxic chemotherapy.","indications":["Gastric cancer or gastroesophageal junction cancer (in combination with CAPOX)","Colorectal cancer (in combination with CAPOX)"],"catalyst":""},{"name":"tislelizumab, and platinum-based chemotherapy","genericName":"tislelizumab, and platinum-based chemotherapy","slug":"tislelizumab-and-platinum-based-chemotherapy","phase":"phase_3","mechanism":"Tislelizumab is a monoclonal antibody that targets and binds to PD-1, blocking its interaction with PD-L1 and PD-L2, thereby enhancing T-cell mediated immune response against cancer cells.","indications":[],"catalyst":""},{"name":"Hydroxycamptothecin for Injection","genericName":"Hydroxycamptothecin for Injection","slug":"hydroxycamptothecin-for-injection","phase":"phase_3","mechanism":"Hydroxycamptothecin inhibits topoisomerase I, preventing DNA relaxation and causing DNA damage in rapidly dividing cancer cells.","indications":["Colorectal cancer","Gastric cancer","Lung cancer","Ovarian cancer"],"catalyst":""},{"name":"Mitomycin for Injection","genericName":"Mitomycin for Injection","slug":"mitomycin-for-injection","phase":"phase_3","mechanism":"Mitomycin is an antibiotic that alkylates DNA, creating cross-links that prevent DNA replication and transcription, leading to cell death.","indications":["Gastric cancer","Colorectal cancer","Bladder cancer","Breast cancer"],"catalyst":""},{"name":"SHR-A2102 and Adebrelimab","genericName":"SHR-A2102 and Adebrelimab","slug":"shr-a2102-and-adebrelimab","phase":"phase_3","mechanism":"SHR-A2102 and Adebrelimab are anti-PD-1 monoclonal antibodies that inhibit the PD-1/PD-L1 interaction.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"TAS-102, Regorafenib , Fruquintinib","genericName":"TAS-102, Regorafenib , Fruquintinib","slug":"tas-102-regorafenib-fruquintinib","phase":"phase_3","mechanism":"TAS-102 is a nucleoside analog that inhibits thymidylate synthase, leading to DNA damage in cancer cells. Regorafenib is a multi-kinase inhibitor that targets angiogenic, stromal, and tumor cells. Fruquintinib is a potent and highly selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2).","indications":["Metastatic colorectal cancer","Gastrointestinal stromal tumor","Colorectal cancer"],"catalyst":""},{"name":"platinum-based dual-agent chemotherapy","genericName":"platinum-based dual-agent chemotherapy","slug":"platinum-based-dual-agent-chemotherapy","phase":"phase_3","mechanism":"Platinum-based dual-agent chemotherapy uses two platinum compounds or a platinum compound combined with another cytotoxic agent to create synergistic DNA damage and cell death in cancer cells.","indications":["Advanced or metastatic solid tumors (specific indication pending phase 3 trial results)"],"catalyst":""},{"name":"Adebrelimab combined with chemotherapy","genericName":"Adebrelimab combined with chemotherapy","slug":"adebrelimab-combined-with-chemotherapy","phase":"phase_2","mechanism":"Immune checkpoint inhibitor","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""},{"name":"Adebrelimab；platinum-based chemotherapy","genericName":"Adebrelimab；platinum-based chemotherapy","slug":"adebrelimab-platinum-based-chemotherapy","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ametinib mesylate","genericName":"Ametinib mesylate","slug":"ametinib-mesylate","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BCG for Injection","genericName":"BCG for Injection","slug":"bcg-for-injection","phase":"phase_3","mechanism":"BCG (Bacillus Calmette-Guérin) is a live attenuated mycobacterial vaccine that stimulates the immune system to recognize and attack cancer cells, particularly in the bladder.","indications":["Non-muscle-invasive bladder cancer (NMIBC), high-grade or recurrent","Carcinoma in situ (CIS) of the bladder"],"catalyst":""},{"name":"BP-102","genericName":"BP-102","slug":"bp-102","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Calcium Folinate Injection","genericName":"Calcium Folinate Injection","slug":"calcium-folinate-injection","phase":"phase_3","mechanism":"Calcium folinate is a reduced form of folic acid that acts as a cofactor in one-carbon transfer reactions, supporting DNA synthesis and cell division.","indications":["Methotrexate toxicity rescue in high-dose methotrexate chemotherapy","Adjunctive therapy in colorectal cancer and other malignancies","Megaloblastic anemia due to folate deficiency"],"catalyst":""},{"name":"Epirubicin Hydrochloride for Injection","genericName":"Epirubicin Hydrochloride for Injection","slug":"epirubicin-hydrochloride-for-injection","phase":"phase_3","mechanism":"Epirubicin intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death in rapidly dividing cancer cells.","indications":["Breast cancer (adjuvant and metastatic)","Gastric cancer","Lymphomas","Other solid tumors as part of combination chemotherapy regimens"],"catalyst":""},{"name":"Fluorouracil Injection","genericName":"Fluorouracil Injection","slug":"fluorouracil-injection","phase":"marketed","mechanism":"Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cancer cell death.","indications":["Colorectal cancer","Breast cancer","Gastric cancer","Pancreatic cancer","Head and neck cancer"],"catalyst":""},{"name":"Gemcitabine and cisplatin / carboplatin","genericName":"Gemcitabine and cisplatin / carboplatin","slug":"gemcitabine-and-cisplatin-carboplatin","phase":"phase_3","mechanism":"Gemcitabine and cisplatin/carboplatin is a chemotherapy combination that damages cancer cell DNA through complementary mechanisms to inhibit tumor growth.","indications":["Advanced or metastatic non-small cell lung cancer","Urothelial carcinoma","Ovarian cancer","Pancreatic cancer"],"catalyst":""},{"name":"Pirarubicin Hydrochloride for Injection","genericName":"Pirarubicin Hydrochloride for Injection","slug":"pirarubicin-hydrochloride-for-injection","phase":"phase_3","mechanism":"Pirarubicin Hydrochloride for Injection is an anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the synthesis of nucleic acids and inducing apoptosis in cancer cells.","indications":["Advanced breast cancer"],"catalyst":""},{"name":"Placebo、CAPOX","genericName":"Placebo、CAPOX","slug":"placebo-capox","phase":"phase_3","mechanism":"CAPOX is a chemotherapy regimen that combines capecitabine and oxaliplatin to treat cancer.","indications":["Metastatic colorectal cancer","Adjuvant treatment of stage III colon cancer"],"catalyst":""},{"name":"SHR-1501 for Injection","genericName":"SHR-1501 for Injection","slug":"shr-1501-for-injection","phase":"phase_3","mechanism":"SHR-1501 is a recombinant human anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 and PD-1/B7-1, thereby releasing immune checkpoint inhibition and enhancing anti-tumor T-cell responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in phase 3)"],"catalyst":""},{"name":"SHR-2017 injection","genericName":"SHR-2017 injection","slug":"shr-2017-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SHR-A1811 for Injection","genericName":"SHR-A1811 for Injection","slug":"shr-a1811-for-injection","phase":"phase_3","mechanism":"SHR-A1811 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"SHR-A2009 ; Aumolertinib","genericName":"SHR-A2009 ; Aumolertinib","slug":"shr-a2009-aumolertinib","phase":"phase_3","mechanism":"Aumolertinib is a third-generation EGFR tyrosine kinase inhibitor that selectively targets EGFR mutations, including T790M resistance mutations, to inhibit tumor cell proliferation.","indications":["Non-small cell lung cancer with EGFR T790M mutation after progression on prior EGFR-TKI therapy","Non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations (first-line and subsequent lines)"],"catalyst":""},{"name":"SHR-A2009 monotherapy","genericName":"SHR-A2009 monotherapy","slug":"shr-a2009-monotherapy","phase":"phase_3","mechanism":"SHR-A2009 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQSFdSY1Vwb1llTndlS2J6Yk5IR0Nsa2dfOFItczREZmg4SXg4c2ZsYjJwVXowdGdCRlVqYlFnbUNycUZkb1FFZDk3em1tVE1IY2ZMVmJjUS1nSlZFQTRuSy1QQ0JsUExwVWplRy1OM3NEaElsTW5kNnVUX0NLWW5zblowMlM4blJuSmNicnI1Y1VnX1d4eFpveW1mSQ?oc=5","date":"2026-03-24","type":"trial","source":"openPR.com","summary":"EGFR + NSCLC Clinical Trial Pipeline Accelerates as 25+ Pharma - openPR.com","headline":"EGFR + NSCLC Clinical Trial Pipeline Accelerates as 25+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQZ2V4cXJvSjB4Q3dqc1lxT1hlR29LODdrSlk3SkRwS05HbjJKcFdYUUhnQ2hzR1RpeEZDd1J6cjNPWHVub1VmdDUzazBBdDI0dmFncGIxMHB6TVdyMnZtM1JtOFc1SExGbDhvQXV6RWd2NnVpbFdteTBIUXEzQUp0OWZYT2EyQ1MzdmFDamU3RVF0d2NubWY0YVl3ZjNXcVAyYkNIQ1F5MWtsRXdBLTRvbGpPVHdZNmFnWDZzNTdPbXgyeGZNQ3N2bmM2Z3EzNTZXRExyWDZvRWE?oc=5","date":"2026-03-20","type":"pipeline","source":"TipRanks","summary":"Hengrui Subsidiary Wins NMPA Nod for New Indication of Innovative HER2 Breast Cancer Drug - TipRanks","headline":"Hengrui Subsidiary Wins NMPA Nod for New Indication of Innovative HER2 Breast Cancer Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNZm11OHR6aDZ1UFhZT2dMT1VtV096NHBNRGVaZHpDM0VnUVhlajhtM1I4cXZFeC1uVHIxalZIYV9LMGNfTjBGLUg0ZHkzTDB6OHQ4Y0U2eC0zdmViS2FGb1F3OWNTdWhOdG8yVDR5ckR6NUZob2FKTDZwdjA4UndoXzZ2LUhTSDBFempqdkR0N3o0Ujc1ckQ1dzJoNW9pZGRPOS1PWlFZd2VSXzJ6OENpdGtn?oc=5","date":"2026-03-13","type":"trial","source":"Endpoints News","summary":"Flagship startup loses CEO to Ipsen; Ionis to shed nearly six decades of board experience - Endpoints News","headline":"Flagship startup loses CEO to Ipsen; Ionis to shed nearly six decades of board experience","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-11","type":"pipeline","source":"The Manila Times","summary":"Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer - The Manila Times","headline":"Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQVHJ6OENrOWhKanJya2tIelhhd0o0TlYxeGlTTld5c2k3Q3NFUGRWQ09iLTNnd01IQnV3dlpJVzllanhtbUZNZ3pkdG5HdVE5OTR0UkJJcDJDNDR0SW1wel9KemNLbkNqZ0sxeEEzUzRObWVVcTg4dFE2UjNqYXo1aUlJTEJXQlFGZ2Fjc1hwRzZqcS1WWGwySDZ5XzZWY1k?oc=5","date":"2025-03-21","type":"regulatory","source":"Fierce Pharma","summary":"FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again - Fierce Pharma","headline":"FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQd3lYXzYzUkhZWXhnTkNXczRIaDB2dXc3cmgybXVOaTRQUjZUMEphSUptS1FBajBTSEFPN3h4aEVIVUlqSXdxSy12alhrUl9JZExfTDdmTzB3NHYtN0J6ZTExTWpreE9adEFwVU5pU0diSFM1OUxvRHlnbkdCZEo2UnhwclF4emItLWJtczZISS1yNlNIaTk2c0dRTC1PZi1CZ0VFXzNFZ2NWc2pa?oc=5","date":"2024-12-30","type":"trial","source":"BioWorld News","summary":"Ideaya, Hengrui join hands in $1B deal for phase I ADC targeting DLL3 - BioWorld News","headline":"Ideaya, Hengrui join hands in $1B deal for phase I ADC targeting DLL3","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOalJtR2w0aVlVUFlGNlo5bEhmT1RxTmRmcm1FV1l0Z0dCQkVrSVN2aWo3dE1ERTBkR00zbzEwWUtGcjFiM2ZTc3NXeHBsbWZEYlU1Qk9QVXpvT21TMy10NlFiWnhXaTh5NXljeVJvalBmMkNBQXpfZzFUWHNJak1FLXlLZHptaGF2M2plZXQ3NjV3cjZLbmVhM3o1Q01CbXRiZFZQTm83Qlcyam93RnBJOFV4ZG9RU3cwZnJZTUhLejdNakZGbFZN?oc=5","date":"2024-10-01","type":"pipeline","source":"prnewswire.com","summary":"PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight - prnewswire.com","headline":"PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOYlhHMVluMnYyaXFqRlFadEo5NEt4R2JPTk9CVVNEeGNzajhUdVRHVkR4VTNERGc3dGpzTkw2bVVkSHNFS1BpT2d1STBSMV9vdHFxU3d5QzRwY2NyZXN0SDg1TG02MkVscXZqSlJtb28zdnNaRWdvQkpMTXZvMzMxbjY5ZldJMFpSMDF3UmE5VlF0dw?oc=5","date":"2024-05-09","type":"trial","source":"Yahoo Finance","summary":"Psoriasis Vulgaris Clinical Trial Pipeline Analysis Demonstrates 50+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - Yahoo Finance","headline":"Psoriasis Vulgaris Clinical Trial Pipeline Analysis Demonstrates 50+ Key Companies at the Horizon Expected to Transform ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxNZHVkZFRxdnFCWHRsT1pkQWJieEItSXN2cHp2T0kzSEszMTdJa3JBVkFqMWFjZjJUR3dycWU1b24xM0htUmpRQXRvT01pQm5aaWtRM2tCMTN6RHVtaGpVdnVpc0pNUVJ0RmRGNHF3a2huUzBRSWRzT3ZHZ1oxdjlZVFkyUGZzNmlXQlN2OVJVV3IzTmg0UmFZaXZwMkJWSjcxa2x6WHlaaFpfNzRtWFdOQW9YNjZJbjlveEN1bk1jRHo0cTFkbTdpUkd6bzlLQ2xDMFUzcEpQcERqWmxxRDhYeFp5dEFLUXNELXlsQm82MXZrOTZvQzZtS19R?oc=5","date":"2021-10-06","type":"trial","source":"GlobeNewswire","summary":"Metastatic Colorectal Cancer Pipeline Review | Clinical Trials Analysis Report 2021 | DelveInsight - GlobeNewswire","headline":"Metastatic Colorectal Cancer Pipeline Review | Clinical Trials Analysis Report 2021 | DelveInsight","sentiment":"positive"}],"patents":[],"drugCount":23,"phaseCounts":{"phase_3":17,"phase_2":1,"phase_1":4,"marketed":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}